13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.

Launched by BRITISH COLUMBIA CANCER AGENCY · Aug 24, 2021

Keywords

ClinConnect Summary

This clinical trial is looking to understand how certain cells in the fluid that builds up in the abdomen (called ascites) of ovarian cancer patients process nutrients. Researchers will give a special form of glucose (a type of sugar) to patients during a routine procedure where this fluid is drained. By studying how the cancer cells and immune cells in the ascites use this glucose, scientists hope to learn more about the tumor environment and potentially improve treatment strategies.

To participate in this study, women aged 65 to 74 who have ovarian cancer at any stage or grade, and who have ascites that needs to be drained, may be eligible. Participants should not have diabetes or any serious blood sugar issues, and they cannot be receiving chemotherapy during the five hours of the study. If you join the study, you will receive the glucose infusion during your regular treatment, and the research team will monitor how your body responds. This study is currently recruiting participants, so if you’re interested, it’s a good idea to talk to your doctor to see if you qualify.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Ovarian cancer
• • Any stage or grade of disease
• • Ascites fluid that requires draining
• • Any treatment regimen
• • Primary or recurrent ascites
• • Understands the concept of the study and give informed consent.
• Exclusion Criteria:
• • Participants must not have diabetes or abnormal hemoglobin A1C levels.
• • The patient's glucose levels must be between 4 - 11.1 mM before administering an infusion. This is to ensure that patients are within normal blood glucose levels, as described by Diabetes Canada.
• • Participants cannot receive chemotherapy treatment during the 5 hour duration of the experiment as it may compromise the integrity of the data.